Patent SG-11201805375P-A (SG)
Title: Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
Inventor: ARMSTRONG CHRISTOPHER
IPC: A61K31/4704
Filed: 2017-02-03
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau „ (10) International Publication Number (43) International Publication Date ^ ^ WO 2017/136774 A1 10 August 2017 (10.08.2017) WIPO I PCT (51) International Patent Classification: A61K 9/16 (2006.01) A61K31/4704 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2017/016582 3 February 2017 (03.02.2017) English English (30) Priority Data: 62/291,480 62/348,102 4 February 2016 (04.02.2016) US 9 June 2016 (09.06.2016) US (71) Applicants: STEM CELL THERANOSTICS, INC. [US/US]; 640 Galveston Drive, Redwood City, CA 94063 (US). CAPELLA BIOSCIENCES, INC. [US/US]; 550 Hamilton Ave., Suite 230, Palo Alto, CA 94301 (US). (72) Inventors: ARMSTRONG, Christopher, G.; 3625 Fel­ lowship Road, Madison, WI 53562 (US). KIM, Kevin, J.; 825 Live Oak Ave, Apt G, Menlo Park, CA 94025 (US). PHAM, Lisa Maria Lucia; 338 South Fremont Street, Apt 417, San Mateo, CA 94401 (US). PARK, Eunhye; 222 Broadway, #1001, Oakland, CA 94607 (US). ZHONG, Zhong; 7 Eastgate Ln, Hingham, MA 02043 (US). HUANG, Guanyi; 4802 Garnet Common, Freemont, CA 94555 (US). WU, Joseph, C.; 444 San Antonio Rd #11A, Palo Alto, CA 94306 (US). ELMER, Sidney, Paul; 550 Hamilton Ave, Suite 230, Palo Alto, CA 94301 (US). VISUTHIKRAISEE, Viwat; 1726 Edgewood Dr., Palo Alto, CA 94303 (US). CADAG, Eithon Michael, G.; Evanston Ave N #5, Seattle, WA 98103 (US). FREE­ MAN, Thomas, Bernard; 311 San Bruno Avenue E, San Bruno, CA 94066 (US). LUM, Pek, Yee; 1726 Edgewood Dr., Palo Alto, CA 94303 (US). (74) Agent: HAK, J. Chang; 550 Hamilton Ave., Suite 230, Palo Alto, CA 94301 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) •rt l> l> o CJ o & (54) Title: PHARMACEUTICAL COMPOSITIONS AND METHODS FOR COUNTERING CHEMOTHERAPY INDUCED CARDIOT OXICIT Y (57) : This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, partic­ ularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3',4',5'-tetrahydroxyflavone, and myricit- rin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different pro­ tective agent or with a cancer treatment (e.g., anthracycline drug).